HD12 for Advanced Stages

Conditions

Hodgkin´s Lymphoma

Keywords

Hodgkin´s Lymphoma, advanced stages

Brief summary

This study is designed to test (1) whether the BEACOPP dosage can be reduced to baseline in the last 4 cycles without loss of effectiveness, and (2) whether consolidating irradiation is necessary following effective chemotherapy.

von Tresckow B, Kreissl S, Goergen H, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P, German Hodgkin Study Group.

2018-10-0127 citations

10.1016/s2352-3026(18)30140-6

Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma.

Bröckelmann PJ, Müller H, Casasnovas O, Hutchings M, von Tresckow B, Jürgens M, McCall SJ, Morschhauser F, Fuchs M, Borchmann P, Moskowitz CH, Engert A.

2017-06-0158 citations

10.1093/annonc/mdx072

Interventions

DRUGCyclophosphamide

DRUGAdriamycin

DRUGEtoposide

DRUGProcarbazine

DRUGPrednisone

DRUGVincristine

DRUGBleomycin

PROCEDUREradiation therapy

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

16 Years to 65 Years

Healthy volunteers

No

Inclusion criteria

* Hodgkin´s lymphoma (histologically proven) * CS(PS) IIB with one or both of the risk factors: 1. bulky mediastinal mass (\> 1/3 of maximum transverse thorax diameter) 2. extranodal involvement * CS(PS) III, IV * written informaed consent

Exclusion criteria

* Leukocytes \<3000/microl * Platelets \<100000/microl * Hodgkin´s Disease as composite lymphoma * Activity index (WHO) \< grade 2

Outcome results

None listed